Panacea Life Sciences Holdings, (PLSH): Valuation
TTM figures as of March 31, 2024
Panacea Life Sciences Holdings, trades at a -76.46% free-cash-flow yield. That FCF yield is higher than 63% of its own month-end history back to 2022.
Earnings yield -361.39%. Piotroski F-score 4 of 9.
51 month-end valuation observations are on file, starting April 2022.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is PLSH cheap versus its own history?
Panacea Life Sciences Holdings, trades at a -76.46% free-cash-flow yield. That FCF yield is higher than 63% of its own month-end history back to 2022.
What is PLSH's free-cash-flow yield?
Panacea Life Sciences Holdings, currently yields -76.46% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.